IMMUNE DESIGN CORP.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2M | $7.2M | $13.3M | $9.5M | $25,000 | $564,000 |
| Operating income | −$57.0M | −$52.8M | −$54.2M | −$39.5M | −$29.9M | −$15.1M |
| Net income | −$54.8M | −$51.9M | −$53.5M | −$39.4M | −$34.2M | −$16.0M |
| Total assets | $101.0M | $153.8M | $114.5M | $116.1M | $78.4M | $31.0M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $92.0M | $139.2M | $95.2M | $109.0M | $66.3M | −$55.8M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 48.1M | 25.4M | 20.2M | 17.0M | 16.9M | 369,460 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −2597.9%
- Net margin
- −2493.5%
- Return on equity
- −59.5%
- Return on assets
- −54.2%
- Return on capital (ROCE)
- −61.9%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.91
- Revenue growth (YoY)
- −69.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Accruals / assets
- −3.1%clean
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Berger Franklin MDirector | Apr 2, 2019 | D | 75,000 | $5.85 |
| Baltimore DavidDirector | Apr 2, 2019 | D | 78,287 | $5.85 |
| Yurasov SergeyOfficer — Sr. VP, Clinic. Devel. & CMO | Apr 2, 2019 | D | 6,136 | $5.85 |
| Brady Stephen ROfficer — EVP, Strategy & Finance | Apr 2, 2019 | D | 17,063 | $5.85 |
| Gombotz WayneOfficer — Chief Development Officer | Apr 2, 2019 | D | 37,068 | — |
| Paya Carlos VOfficer — President and CEO | Apr 2, 2019 | D | 35,576 | $5.85 |
| Ter Meulen Jan HenrikOfficer — Chief Scientific Officer | Apr 2, 2019 | D | 14,620 | $5.85 |
| Coleman Lewis WDirector | Apr 2, 2019 | D | 175,000 | $5.85 |
| Column Group L P10% owner | Apr 2, 2019 | U | 6.6M | $5.85 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 2, 2019
- Entered a material agreement · Other material eventFeb 21, 2019
- Director / officer changeJan 8, 2019
- Terminated a material agreementDec 10, 2018
- Director / officer changeNov 13, 2018
- Results of operationsNov 6, 2018
- Other material eventOct 11, 2018
- Director / officer changeSep 4, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BApr 12, 2019
- EFFECTApr 8, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4FORM 4 SUBMISSIONApr 4, 2019
- 4PRIMARY DOCUMENTApr 2, 2019
- S-8 POSApr 2, 2019